Title

Shanghai Registry of Acute Coronary Events
Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS
  • Phase

    N/A
  • Study Type

    Observational
  • Status

    Terminated
  • Intervention/Treatment

    tirofiban ...
  • Study Participants

    20000
SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.
consecutive patients with STEMI who presented symptoms within 12 hours and treated by primary PCI in Shanghai, were enrolled in the prospective sysytem. Several strategies were applied in these patients, including physician vs. patient transfer strategy, upsteam vs. downstream strategy, Firebird stent vs. Excel stent (bio-absorbable SES), etc. Once the patient was randomized to one of these study, he will be denied to the others. Clinical and angiographic outcomes were compared, with the final purpose to find an optimal strategy in treating AMI patients.
Study Started
Mar 31
2005
Primary Completion
Jan 31
2018
Anticipated
Last Update
Oct 13
2016
Estimate

Device drug-eluting stent

drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

  • Other names: Cypher stent, Taxus stent, Firebird stent, Excel stent

Drug Tirofiban

upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading

1 None

patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy

2 None

patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI

3 None

patients with non-ST-elevation ACS treated by immediate PCI

4 None

patients with non ST-elevation ACS treated by elective PCI

5 None

STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.

6 None

STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).

Population

patients admitted to the hospital with acute coronary syndrome

Criteria

Inclusion Criteria:

patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment

Exclusion Criteria:

non ACS patients;
complicated with other lethal disease
predicted life span less than 12 months
known allergy history to any anti-platelet or anti-thrombin medicine
unconscious at the time of arrival at the hospital
No Results Posted